Skip to main content
Smart Investors Daily
NU

NYSE · NUVB

Nuvation Bio Inc.

Healthcare · Biotechnology

$3.99

Down-$0.07 (-1.72%)

Updated Nov 16, 2026, 11:49 AM

SID Score

4.0/10

Composite research score

Smart Money

58/100

Neutral

Market cap
2.83B
P/E ratio
-13.02
Dividend yield
0.00%
52-week range
$3.95 – $7.58
Volume
3.09M
Avg. volume
8.66M

Price performance · NUVB

NUVB price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 13, 2026

NUVB closed at $3.99 after 20 trading sessions, down 10.94% for the selected period.

Last close
$3.99
Period change
-10.94%
Period low
$3.99
Period high
$4.85
Daily close
View OHLC price history
NUVB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 13, 2026$4.03$4.115$3.945$3.993.09M
Nov 12, 2026$4.22$4.22$4.03$4.065.64M
Nov 11, 2026$4.27$4.38$4.22$4.292.95M
Nov 10, 2026$4.23$4.355$4.1101$4.203.48M
Nov 9, 2026$4.23$4.43$4.075$4.355.33M
Nov 6, 2026$4.21$4.329$3.975$4.165.34M
Nov 5, 2026$4.459$4.81$4.18$4.198.42M
Nov 4, 2026$4.70$4.75$4.52$4.738.41M
Nov 3, 2026$4.62$4.785$4.61$4.695.14M
Nov 2, 2026$4.80$4.85$4.59$4.593.72M
Oct 30, 2026$4.75$4.805$4.60$4.765.06M
Oct 29, 2026$4.65$4.835$4.64$4.776.5M
Oct 28, 2026$4.48$4.60$4.425$4.595.22M
Oct 27, 2026$4.51$4.59$4.36$4.555.06M
Oct 26, 2026$4.62$4.68$4.48$4.513.66M
Oct 23, 2026$4.62$4.66$4.44$4.573.19M
Oct 22, 2026$4.83$4.91$4.655$4.705.81M
Oct 21, 2026$4.77$4.96$4.72$4.854.5M
Oct 20, 2026$4.51$4.82$4.46$4.776.85M
Oct 19, 2026$4.48$4.60$4.345$4.484.22M

Latest NUVB news

The latest Smart Investors Daily articles mentioning NUVB.

NUVB research

Overview

Company profile and research snapshot.

Company profile

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$13.00
Implied upside
—
Analysts
—
NUVB recent ratings
DateFirmRatingTarget
Nov 5, 2026RBC CapitalOutperform—
Sep 30, 2026CitigroupBuy—
Sep 16, 2026CitizensMarket Outperform—
Sep 16, 2026WedbushOutperform—
Aug 21, 2026Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 8, 2026

What Nuvation Bio (NUVB) Said on Its Q3 Earnings Call

Nuvation Bio (NYSE:NUVB) reported $45 million in third-quarter 2026 revenue as U.S. sales of lung cancer treatment IBTROZI rose 18% from the previous quarter, even as the company said new patient starts declined across the broader ROS1 treatment market. IBTROZI generated $27.5 million in net U.S. p

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.